دورية أكاديمية
أعرض في EDS

Predictors of persistent symptoms after mRNA SARS-CoV-2 vaccine-related myocarditis (myovacc registry).

التفاصيل البيبلوغرافية
العنوان: Predictors of persistent symptoms after mRNA SARS-CoV-2 vaccine-related myocarditis (myovacc registry).
المؤلفون: Schroth D; Departments of Radiology and Cardiology, Theresien Hospital, Mannheim, Germany., Garg R; Departments of Medicine and Diagnostic Radiology, McGill University Health Centre (MUHC), Montreal, QC, Canada., Bocova X; Departments of Radiology and Cardiology, Theresien Hospital, Mannheim, Germany., Hansmann J; Departments of Radiology and Cardiology, Theresien Hospital, Mannheim, Germany., Haass M; Departments of Radiology and Cardiology, Theresien Hospital, Mannheim, Germany., Yan A; Division of Cardiology, Unity Health Toronto, St. Michael's Hospital, Toronto, ON, Canada., Fernando C; Division of Cardiology, Unity Health Toronto, St. Michael's Hospital, Toronto, ON, Canada., Chacko B; Department of Medical Imaging, Sunnybrook Health Sciences Center, Toronto, ON, Canada., Oikonomou A; Department of Medical Imaging, Sunnybrook Health Sciences Center, Toronto, ON, Canada., White J; Stephenson Cardiac Imaging Centre, Foothills Medical Centre, Calgary, AB, Canada., Alhussein MM; Stephenson Cardiac Imaging Centre, Foothills Medical Centre, Calgary, AB, Canada., Giusca S; Department of Cardiology, GRN Hospital, Weinheim, Germany., Ochs A; Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, Heidelberg, Germany., Korosoglou G; Department of Cardiology, GRN Hospital, Weinheim, Germany., André F; Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg, Heidelberg, Germany., Friedrich MG; Departments of Medicine and Diagnostic Radiology, McGill University Health Centre (MUHC), Montreal, QC, Canada., Ochs M; Departments of Radiology and Cardiology, Theresien Hospital, Mannheim, Germany.
المصدر: Frontiers in cardiovascular medicine [Front Cardiovasc Med] 2023 Jun 21; Vol. 10, pp. 1204232. Date of Electronic Publication: 2023 Jun 21 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101653388 Publication Model: eCollection Cited Medium: Print ISSN: 2297-055X (Print) Linking ISSN: 2297055X NLM ISO Abbreviation: Front Cardiovasc Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media S.A., [2014]-
مستخلص: Aims: Epidemiological surveillance has raised safety concerns for mRNA SARS-CoV-2-vaccination-related myocarditis. We aimed to analyze epidemiological, clinical and imaging findings associated with clinical outcomes in these patients in an international multi-center registry (NCT05268458).
Methods and Results: Patients with clinical and CMR diagnosis of acute myocarditis within 30 days after mRNA SARS-CoV-2-vaccination were included from five centers in Canada and Germany between 05/21 and 01/22. Clinical follow-up on persistent symptoms was collected. We enrolled 59 patients (80% males, mean age 29 years) with CMR-derived mild myocarditis (hs-Troponin-T 552 [249-1,193] ng/L, CRP 28 [13-51] mg/L; LVEF 57 ± 7%, LGE 3 [2-5] segments). Most common symptoms at baseline were chest pain (92%) and dyspnea (37%). Follow-up data from 50 patients showed overall symptomatic burden improvement. However, 12/50 patients (24%, 75% females, mean age 37 years) reported persisting symptoms (median interval 228 days) of chest pain ( n  = 8/12, 67%), dyspnea ( n  = 7/12, 58%), with increasing occurrence of fatigue ( n  = 5/12, 42%) and palpitations ( n  = 2/12, 17%). These patients had initial lower CRP, lower cardiac involvement in CMR, and fewer ECG changes. Significant predictors of persisting symptoms were female sex and dyspnea at initial presentation. Initial severity of myocarditis was not associated with persisting complaints.
Conclusion: A relevant proportion of patients with mRNA SARS-CoV-2-vaccination-related myocarditis report persisting complaints. While young males are usually affected, patients with persisting symptoms were predominantly females and older. The severity of the initial cardiac involvement not predicting these symptoms may suggest an extracardiac origin.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(© 2023 Schroth, Garg, Bocova, Hansmann, Haass, Yan, Fernando, Chacko, Oikonomou, White, Alhussein, Giusca, Ochs, Korosoglou, Andre, Friedrich and Ochs.)
References: Front Cardiovasc Med. 2022 Aug 17;9:990108. (PMID: 36061550)
Immunology. 2022 Aug;166(4):429-443. (PMID: 35470422)
Eur J Heart Fail. 2022 Nov;24(11):2000-2018. (PMID: 36065751)
Evid Rep Technol Assess (Full Rep). 2014 Jul;(215):1-740. (PMID: 30257278)
J Pers Med. 2021 Oct 28;11(11):. (PMID: 34834458)
JAMA Cardiol. 2021 Oct 1;6(10):1202-1206. (PMID: 34185045)
JACC Cardiovasc Imaging. 2021 Sep;14(9):1856-1861. (PMID: 34246586)
Front Cardiovasc Med. 2021 Feb 02;8:636843. (PMID: 33604359)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Front Cardiovasc Med. 2021 Nov 30;8:745758. (PMID: 34917659)
JAMA Cardiol. 2019 Oct 1;4(10):1034-1042. (PMID: 31389986)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
JACC Basic Transl Sci. 2022 Mar;7(3):294-308. (PMID: 35165665)
N Engl J Med. 2021 Dec 2;385(23):2132-2139. (PMID: 34614329)
Cell. 2018 Nov 29;175(6):1701-1715.e16. (PMID: 30449622)
JAMA Cardiol. 2021 Oct 1;6(10):1196-1201. (PMID: 34185046)
Vaccine. 2015 Aug 26;33(36):4398-405. (PMID: 26209838)
Bioessays. 2011 Nov;33(11):791-802. (PMID: 21953569)
Rev Esp Cardiol. 2022 May;75(5):444-446. (PMID: 34876772)
J Cardiovasc Magn Reson. 2020 Dec 14;22(1):87. (PMID: 33308262)
Eur Radiol. 2022 Jul;32(7):4352-4360. (PMID: 35230520)
N Engl J Med. 2021 Dec 2;385(23):2140-2149. (PMID: 34614328)
J Cardiovasc Magn Reson. 2021 Sep 9;23(1):101. (PMID: 34496880)
Int J Cardiol. 2018 Dec 15;273:183-186. (PMID: 30236504)
Clin Microbiol Infect. 2022 Apr;28(4):611.e9-611.e16. (PMID: 34763058)
Arch Intern Med. 2008 Dec 8;168(22):2405-14. (PMID: 19064822)
MMWR Morb Mortal Wkly Rep. 2021 Jul 09;70(27):977-982. (PMID: 34237049)
Hum Genomics. 2019 Jan 8;13(1):2. (PMID: 30621780)
J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176. (PMID: 30545455)
Mayo Clin Proc. 2022 Mar;97(3):454-464. (PMID: 35135695)
N Engl J Med. 2021 Sep 16;385(12):1078-1090. (PMID: 34432976)
Front Cardiovasc Med. 2022 May 31;9:877416. (PMID: 35711381)
J Womens Health (Larchmt). 2022 May;31(5):620-630. (PMID: 35333613)
Circulation. 2020 Oct 27;142(17):1609-1611. (PMID: 32877231)
Circulation. 2021 Nov 30;144(22):e368-e454. (PMID: 34709928)
Circulation. 2002 Jan 29;105(4):539-42. (PMID: 11815441)
JAMA. 2021 Sep 28;326(12):1210-1212. (PMID: 34347001)
Vaccine. 2021 Jun 29;39(29):3790-3793. (PMID: 34092429)
Circulation. 2021 Aug 10;144(6):502-505. (PMID: 34133885)
BMJ. 2021 Dec 16;375:e068665. (PMID: 34916207)
Clin Immunol. 2020 Aug;217:108480. (PMID: 32461193)
فهرسة مساهمة: Keywords: covid vaccination; myocarditis; outcome; persistent symptoms; predictors
سلسلة جزيئية: ClinicalTrials.gov NCT05268458
تواريخ الأحداث: Date Created: 20230707 Latest Revision: 20230718
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10321411
DOI: 10.3389/fcvm.2023.1204232
PMID: 37416926
قاعدة البيانات: MEDLINE
الوصف
تدمد:2297-055X
DOI:10.3389/fcvm.2023.1204232